Supernus Pharmaceuticals
SUPN
28.61
+0.26
+0.92%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
28.61
+0.26
+0.92%
Periodic snapshot; not a real-time feed.
· 2026-11-20 16:48
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 6 analysts
Buy
Avg price target 52.60 +83.9%
Price target rangecurrent 28.61
Low37.00
Avg52.60
High87.00
Buy 83%
Hold 17%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | BofA Securities | -- | Buy | 47.00 |
| 2026-11-04 | Piper Sandler | -- | Buy | 47.00 |
| 2026-11-04 | Stifel | -- | Hold | 37.00 |
| 2026-11-03 | Cantor Fitzgerald | -- | Buy | 87.00 |
| 2026-10-30 | BofA Securities | -- | Buy | -- |
| 2026-10-30 | Stifel | -- | Hold | 55.00 |
| 2026-10-28 | Barclays | -- | Buy | 45.00 |
| 2026-10-21 | TD Cowen | -- | Buy | 65.00 |
| 2026-10-15 | BofA Securities | -- | Buy | 55.00 |
| 2026-10-12 | BofA Securities | -- | Buy | 60.00 |
| 2026-09-17 | Craig-Hallum | -- | Buy | -- |
| 2026-08-03 | TD Cowen | -- | Buy | 65.00 |
| 2026-07-27 | Piper Sandler | -- | Buy | 66.00 |
| 2026-07-13 | BofA Securities | -- | Buy | 63.00 |
| 2026-07-09 | Cantor Fitzgerald | -- | Buy | 67.00 |
| 2026-06-04 | Piper Sandler | -- | Buy | 66.00 |
| 2026-05-06 | Piper Sandler | -- | Buy | 66.00 |
| 2026-05-06 | Stifel | -- | Hold | 55.00 |
| 2026-05-05 | TD Cowen | -- | Buy | 65.00 |
| 2026-04-27 | Piper Sandler | -- | Buy | 66.00 |
| 2026-04-23 | TD Cowen | -- | Buy | 65.00 |
| 2026-04-13 | Piper Sandler | -- | Buy | 66.00 |
| 2026-02-25 | TD Cowen | -- | Buy | 65.00 |
| 2026-02-25 | Stifel | -- | Hold | 55.00 |
| 2026-02-24 | TD Cowen | -- | Buy | 65.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | After close | ±12.09% | +0.34% (in line) |
| 2026/Q2 | 2026-08-04 | After close | ±11.59% | +6.11% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±12.36% | +2.58% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±13.52% | +1.72% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±11.23% | +0.16% (in line) |
| 2025/Q2 | 2025-08-05 | After close | -- | +0.92% |
| 2025/Q1 | 2025-05-06 | After close | ±12.30% | -1.88% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±8.52% | +3.87% (in line) |
| 2024/Q3 | 2024-11-04 | After close | ±10.88% | +0.33% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±10.67% | -2.22% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±11.47% | +0.51% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±20.19% | -1.57% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.
Supernus Pharmaceuticals discussion 0 comments